Oncimmune Gets Medicare Reimbursement for Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer detection company Oncimmune today said that it has received Medicare coverage for a new blood-based test that it claims can detect cancers as much as five year earlier than current testing methods.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.

Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.

Proove Biosciences had allegedly been paying doctors to perform its opioid risk and other genetic tests, Stat News reports.

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.